VBI Vaccines Inc VBIVQ

Healthcare Biotechnology

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

GREY:VBIVQ - Post by User

VBI Vaccines Inc

Bullboard Posts

Post by cypress44on Aug 02, 2016 10:29am

849 Views

Post# 25102176

curb any enthusiasm

Called a biotech buddy who was up on the VBI / Scivac / Levon deal who said:

VBI has good products and tech but not to expect any FDA / EMA approval before Q3 2017
The zika virus cure could utilize their platform but a long long way off
The commercial sales side of Scivac was a joke and the valuation of 50c for the deal with Levon was way high
Levon management did not do their due diligence
A double kick in the nuts for original Levon shareholders, the stock freefall last fall and recent consolidation done at 12.5c, gives their strike price near $20
Anticipated at least 18 - 24 months for Levon shareholders to get in the money depending on market conditions

What a disaster! Anyone know any lawyers…. Monsieur Temblay?

Bullboard Posts

How one company is disrupting PoC testing